Hulio (adalimumab)

pCPA File Number: 21318

Negotiation Status:

Concluded with an LOI

Indication(s):

Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis

Sponsor/Manufacturer:

BGP Pharma ULC

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2020-11-09

Negotiation Process Concluded:

2021-01-20